Analytical Data
-
Gene name
INSL5
- Application
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9WUG6
-
Expression Region
Arg23~Cys135
-
Molecular Weight
43.15kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Insulin-like peptide 5 (INSL5) is a member of the insulin superfamily and plays a significant role in metabolic regulation and body weight homeostasis. Initially identified in the gut, INSL5 is expressed in specific neuroendocrine cells and is believed to be involved in various physiological processes, including glucose metabolism and energy balance. Recent studies have highlighted its potential involvement in signaling pathways that affect appetite control and insulin sensitivity. The interest in recombinant INSL5 proteins has surged as researchers aim to elucidate its biological functions and therapeutic potential. Understanding the mechanisms of INSL5 could pave the way for developing novel treatment strategies for obesity and type 2 diabetes, where dysregulation of energy homeostasis occurs. Additionally, the recombinant production of INSL5 protein allows for detailed studies on its structure-function relationships and interactions with its receptor, providing insights into its role within the endocrine system and its potential as a biomarker for metabolic disorders. Overall, the study of INSL5 and the use of recombinant protein technology are crucial for advancing our knowledge of metabolic diseases and identifying new avenues for intervention.
